Cancer

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features This study is currently recruiting participants. Verified by Neotropix, September 2008 This is the first study in man of Seneca Valley Virus, a virus which seeks and kills certain tumors in non-human model systems. Subjects in this trial will be patients with advanced cancer displaying certain specified neuroendocrine features, pathologically; they will have exhausted standard methods of treatment for their tumor. The primary purpose of the trial is to determine if the virus may be administered safely. Additional purposes are to learn about the distribution of the virus in the body, the elimination of the virus from the body, the immune response to the virus and whether the virus might have some beneficial effects upon the tumors which the patients have. The first patients will be treated with low amounts of virus and subsequent patients may receive higher amounts. At the end of the trial, it is intended to select a dose for further study.

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL. J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33. Epub 2007 Oct 30. PMID: 17971529 doi:10.1093/jnci/djm198

Phase I trial of Seneca Valley Virus (NTX-010), a newly discovered systemically deliverable oncolytic picornavirus, in patients with solid tumors with neuroendocrine features. C. M. Rudin, D. Lansey, K. D. Burroughs, L. M. Hales, J. R. Neefe, P. S. Reddy and P. L. Hallenbeck Johns Hopkins Univ, Baltimore, MD; Neotropix, Inc., Malvern, PA. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 18014 © 2007 American Society of Clinical Oncology. Conclusions: NTX-010 is a novel first-in-class anticancer virus with selective tropism for tumors with neuroendocrine features. This is the first anticancer virus given intravenously with documented selective intratumoral infection and replication. Administration was well tolerated. Safety data and viral kinetics will be presented.

Neotropix™ Inc. develops and commercializes systemically deliverable oncolytic viruses for the treatment of solid tumors. Capitalizing on its unique sources of naturally occurring viruses that selectively target tumors, the Company has the knowledge and skills to translate these discoveries into commercial products. Neotropix is committed to making a difference in the lives of cancer patients.

nightsurfer's cancer related Diigo list

new (March 24th) report in Clinical Cancer Research, a journal of the American Association for Cancer Research, shows that Omega-3 fatty acids appear protective against advanced prostate cancer. Dr. John S. Witte, Ph.D., professor of epidemiology and biostatistics at the University of California San Francisco, says that previous research has shown protection against prostate cancer, but that this is one of the first studies to show protection against advanced prostate cancer.

Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk. Fradet V, Cheng I, Casey G, Witte JS. Clin Cancer Res. 2009 Mar 24. [Epub ahead of print] PMID: 19318492 DOI: 10.1158/1078-0432.CCR-08-2503

Bioavailability and Kinetics of Sulforaphane in Humans after Consumption of Cooked versus Raw Broccoli Martijn Vermeulen*, Ineke W. A. A. Klpping-Ketelaars†, Robin van den Berg‡ and Wouter H. J. Vaes J. Agric. Food Chem., 2008, 56 (22), pp 10505-10509 Publication Date (Web): October 24, 2008 (Article) DOI: 10.1021/jf801989e

A collaborative study led by UCL (University College London) shows that the compound - inositol pentakisphosphate - found in beans, nuts and cereals inhibits a key enzyme (phosphoinositide 3-kinase) involved in tumour growth. The findings, published in the latest issue of Cancer Research, suggest that a diet enriched in such foods could help prevent cancer, while the inhibitor offers a new tool for anti-cancer therapy.

Meat intake and mortality: a prospective study of over half a million people. Sinha R, Cross AJ, Graubard BI, Leitzmann MF, Schatzkin A. Arch Intern Med. 2009 Mar 23;169(6):562-71. PMID: 19307518 Red and processed meat intakes were associated with modest increases in total mortality, cancer mortality, and cardiovascular disease mortality

A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Chavarro JE, Stampfer MJ, Hall MN, Sesso HD, Ma J. Am J Clin Nutr. 2008 Nov;88(5):1297-303. PMID: 18996866 Conclusion: These results suggest that fish intake is unrelated to prostate cancer incidence but may improve prostate cancer survival.

ScienceDaily (Apr. 5, 2009) - Docosahexanoic acid (DHA), an omega-3 fatty acid found in fish oils, has been shown to reduce the size of tumours and enhance the positive effects of the chemotherapy drug cisplatin, while limiting its harmful side effects. The rat experiments provide some support for the plethora of health benefits often ascribed to omega-3 acids.

Nutritional intervention with omega-3 Fatty acids in a case of malignant fibrous histiocytoma of the lungs. Pardini RS, Wilson D, Schiff S, Bajo SA, Pierce R. Nutr Cancer. 2005;52(2):121-9. PMID: 16201843

Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ, Eibl G. Pancreas. 2008 May;36(4):353-62. PMID: 18437081 doi: 10.1097/MPA.0b013e31815ccc44

Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K. Neoplasia. 2006 Feb;8(2):112-24. PMID: 16611404

Stem cells are cells with the potential to develop into many different types of cells in the body. They serve as a repair system for the body. There are two main types of stem cells: embryonic stem cells and adult stem cells. Doctors and scientists are excited about stem cells because they have potential in many different areas of health and medical research. Studying stem cells may help explain how serious conditions such as birth defects and cancer come about. Stem cells may one day be used to make cells and tissues for therapy of many diseases, including Parkinson's disease, Alzheimer's disease, spinal cord injury, heart disease, diabetes and arthritis.

Stem cells are unprogrammed cells in the human body that can be described as "shape shifters." These cells have the ability to change into other types of cells. Stem cells are at the center of a new field of science called regenerative medicine. Because stem cells can become bone, muscle, cartilage and other specialized types of cells, they have the potential to treat many diseases, including Parkinson's, Alzheimer's, diabetes and cancer. Eventually, they may also be used to regenerate organs, reducing the need for organ transplants and related surgeries. "Stem cells are like little kids who, when they grow up, can enter a variety of professions," Dr. Marc Hedrick of the UCLA School of Medicine says. "A child might become a fireman, a doctor or a plumber, depending on the influences in their life -- or environment. In the same way, these stem cells can become many tissues by making certain changes in their environment."

Mushrooms have traditionally been valued in Asia for their nutritional and medicinal qualities. The Coriolus versicolor or "Turkey Tail" mushroom has been investigated in numerous laboratory, animal and human clinical studies. Most of these studies have demonstrated that it does appear to have significant antimicrobial, antiviral and antitumor properties when used as a supplement to chemotherapy and/or radiotherapy. Human trials have included randomization, a process that decreases bias, but only one has used blinding, which would make them even more protected against biases.

The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center was established in 1999 to complement mainstream medical care and address the emotional, social, and spiritual needs of patients and families. The Service includes: patient and outpatient clinical care research, and education and training. In addition, the Service provides unique access to otherwise unavailable information about over-the-counter products and unproven cancer treatments and their impact in the context of cancer care via our About Herbs database

Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Am J Clin Nutr. 2007 Jun;85(6):1586-91. Erratum in: Am J Clin Nutr. 2008 Mar;87(3):794. PMID: 17556697 Conclusions: Improving calcium and vitamin D nutritional status substantially reduces all-cancer risk in postmenopausal women.